NCT03622658 - Efficacy and Safety of Namilumab for Moderate-to-severe Axial Spondyloarthritis | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

September 6, 2018

Primary Completion Date

February 4, 2020

Study Completion Date

February 4, 2020

Conditions

Axial Spondyloarthritis

Interventions

BIOLOGICAL

Placebo

Placebo solution for subcutaneous injection.

BIOLOGICAL

Namilumab

Namilumab solution for subcutaneous injection

Trial Locations (9)

Royal United Hospitals Bath, Bath

University Hospital Birmingham, Birmingham

University Hospital Coventry and Warwickshire, Coventry

Northwick Park Hospital, London

Whipps Cross Hospital, London

Norfolk and Norwich University Hospital, Norwich

Oxford University Hospital, Oxford

Royal Berkshire Hospital, Reading

Haywood Hospital, Stoke-on-Trent